Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1A | P48039 | 8/20 | 0.44 |
| ▸ | MTNR1B | P49286 | 7/20 | 0.44 |
| ▸ | NQO2 | P16083 | 4/20 | 0.44 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.42 |
| ▸ | ATM | Q13315 | 1/20 | 0.42 |
| ▸ | PPARD | Q03181 | 2/20 | 0.41 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3409346 | 0.83 | OPRM1 (0.46) | MTNR1AMTNR1BNQO2 | |
| SCHEMBL24650762 | 0.83 | MTNR1A (0.45) | MTNR1AMTNR1BNQO2FFAR4ATM | |
| SCHEMBL9467265 | 0.79 | MTNR1A (0.52) | MTNR1AMTNR1BNQO2PPARD | |
| SCHEMBL4261860 | 0.78 | MTNR1A (0.62) | MTNR1AMTNR1BNQO2 | |
| SCHEMBL3407256 | 0.76 | OPRM1 (0.42) | MTNR1AMTNR1BNQO2 | |
| SCHEMBL20109885 | 0.76 | OPRM1 (0.48) | — | |
| SCHEMBL3843777 | 0.75 | OPRM1 (0.48) | — | |
| SCHEMBL3843779 | 0.75 | OPRM1 (0.48) | — | |
| SCHEMBL1520733 | 0.74 | SIRT1 (0.45) | MTNR1AMTNR1BNQO2 | |
| SCHEMBL24651103 | 0.73 | MTNR1A (0.46) | MTNR1AMTNR1BNQO2PTGDR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2260017-A1 | CONFORMATIONALLY CONSTRAINED CARBOXYLIC ACID DERIVATIVES USEFUL FOR TREATING METABOLIC DISORDERS | Amgen, Inc (US) | 2010-12-15 | — | — | EP | disclosed |
| WO-2009111056-A1 | CONFORMATIONALLY CONSTRAINED CARBOXYLIC ACID DERIVATIVES USEFUL FOR TREATING METABOLIC DISORDERS | AMGEN INC. (US) | 2009-09-11 | — | — | WO | disclosed |